Treatment of fragile x syndrome
AssigneeUTI Limited Partnership
InventorRaymond W. TURNER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).
Claims21
A recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide and a FMRP(298) polypeptide, or fragment or variants thereof.
A fusion polypeptide comprising or consisting of tat-FMRP(298) MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDINESD EVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKPATKDTFH KIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKRAHMLIDMHFRSL RTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGANIQQARKVPGVTAIDLDE DTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGSGGGYGRKKRRQRRR (SEQ ID NO:
- 1), or fragments or variants thereof.
A polynucleotide molecule comprising or consisting of a sequence that encodes a cell penetrating polypeptide and a FMRP(298) polypeptide, or fragment or variants thereof.
A polynucleotide molecule comprising or consisting of a sequence that encodes a fusion polypeptide comprising or consisting of tat-FMRP(298) (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.